Lidocaine Hydrochloride by is a Prescription medication manufactured, distributed, or labeled by Gensco Laboratories, LLC. Drug facts, warnings, and ingredients follow.
LDO Plus contains Lidocaine Hydrochloride USP and is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of LDO Plus.
Do not use LDO Plus on traumatized mucosa or in the presence of secondary bacterial infection of the area of proposed application.
Do not use this product if you are allergic to any ingredients. If condition worsens or does not improve within 7 days, consult a physician. Do not use on children under 2 years of age without consulting a physician.
Avoid contact with eyes. Do not use in large quantities.
For external use only. Not for ophthalmic use.
Keep out of reach of children.
If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. LDO Plus Hydrogel should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of Lidocaine Hydrochloride USP. In case of accidental ingestion get medical help or contact poison control center right away.
Studies of lidocaine in animals to evaluate the carcinogenic potential of the effect on fertility have not been conducted.
Teratogenic Effects. Pregnancy Category B. Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by Lidocaine Hydrochloride USP. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering Lidocaine Hydrochloride USP to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lidocaine Hydrochloride USP. is administered to a nursing woman.
Dosage in children should be reduced, commensurate with age, body weight and physical condition. Caution must be taken to avoid over dosage when applying LDO Plus to large areas of injured or abraded skin, since the systemic absorption of Lidocaine Hydrochloride USP may be increased under such conditions.
Adverse experiences following the administration of Lidocaine Hydrochloride USP are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient.
Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:
CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of lidocaine is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.
Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest.
Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to the local anesthetic agent or to other components in the formulation. Allergic reactions as a result of sensitivity to lidocaine are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.
LDO Plus (Lidocaine HCl USP 4%)
1/2 oz (15g) 15mL Airless Pump - NDC: 35781-0500-1
1.00 oz (30g) 30mL Airless Pump - NDC: 35781-0500-3
3.00 oz (90g) 90mL Airless Pump - NDC: 35781-0500-9
Gensco Labratories, LLC
8550 NW 33rd St Suite 200
Doral, FL 33122
LIDOCAINE HYDROCHLORIDE
dressing, wound and burn, hydrogel w/drug and/or biologic gel |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
Labeler - Gensco Laboratories, LLC (831042325) |
Registrant - Gensco Laboratories, LLC (831042325) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Gensco Laboratories, LLC | 831042325 | manufacture(35781-0500) |